![]() |
|
|
Vol. 298, Issue 2, 790-796, August 2001
Division of Medicinal Chemistry and Natural Products, School of
Pharmacy, University of North Carolina, Chapel Hill, North Carolina
(B.J.B., A.E.E., I.H.H.); and Department of Chemistry, North Carolina
Central University, Durham, North Carolina (R.A.I.)
Inosine 5'-monophosphate dehydrogenase (IMPDH), the rate-limiting
enzyme in the de novo pathway for synthesis of guanine nucleotides, is
essential for normal cell proliferation and function. New derivatives of the 1,5-diazabicyclo[3.1.0]hexane-2,4-diones were synthesized and
examined for antiproliferative effects and selective inhibition of
human IMPDH type II activity. The
3,3-disubstituted-6,6-pentamethylene-1,5-diazabicyclo[3.1.0]hexane-2,4-diones proved to be effective antiproliferative agents in tumor cell lines
derived from murine and human leukemias, lymphomas, uterine carcinoma,
glioma, and breast effusion with ED50 values (concentration of compound that inhibits 50% of cell growth) ranging from 3.3 to 16 µM. The agents acted as antimetabolites suppressing de novo purine
biosynthesis at the key regulatory enzyme IMPDH, resulting in the
specific suppression of dGTP pool levels by 19 to 64% and DNA
synthesis by 39 to 68%. The derivatives were specific inhibitors of
IMPDH type II activity as opposed to type I, acting in a competitive manner with respect to inosine 5'-monophosphate,
Ki values of 44.2 to 62 µM. In addition,
effects of agents on Tmolt4 cell growth and DNA synthesis
could be reversed by coincubation with guanosine. Unlike mycophenolic
acid and tiazofurin, the
6,6-pentamethylene-1,5-diazabicyclo[3.1.0]hexane-2,4-diones specifically targeted type II IMPDH, where activity is increased in
replicating or neoplastic cells, and did not suppress type I activity,
where expression is relatively unaffected by cell proliferation or
transformation. Agents were not inhibitors of normal human lung
fibroblast cell growth, WI-38, most likely due to the observed isoform selectivity.